Retatrutide (developer code LY3437943) is the first peptide scaffold in published clinical research to simultaneously activate the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR) within a single molecule. The third arm, glucagon receptor agonism, is the feature that separates retatrutide from tirzepatide and positions it as a genuinely new pharmacological tool for metabolic research rather than an incremental extension of existing dual-agonist chemistry.
This guide covers retatrutide as a research compound: molecular design, triple-receptor pharmacology, the preclinical and clinical evidence built on the Coskun 2022 discovery paper and the Jastreboff 2023 Phase 2 trial, the ongoing TRIUMPH program, and laboratory handling notes. For broader class comparison, see our GLP-1 research pillar guide.
All information in this article is intended for laboratory and research purposes only. It is not medical advice, not a dosing recommendation for humans, and not an endorsement of any non-research use. Clinical trial data is summarised strictly as research context and attributed to the published source.
Cluster navigation
- GLP-1 research pillar guide (post 1288) – class overview and comparison
- Semaglutide vs tirzepatide vs retatrutide head-to-head (post 2054)
- TRIUMPH-4 Phase 3 results (post 1781)
- Research dosing protocols for incretin peptides (post 1265)
- GLP-1 class pharmacokinetics (post 1975)
- Lyophilized peptide reconstitution guide
Molecular design of retatrutide
Retatrutide is a 39-amino-acid synthetic peptide built on a GIP backbone, engineered to bind all three target receptors with balanced potency. The design problem is non-trivial: a single scaffold has to preserve recognition at three structurally distinct class B GPCRs without losing potency at any one, while also carrying a half-life extension strategy compatible with once-weekly exposure.
The Coskun et al. 2022 discovery paper in Cell Metabolism (PMID: 35985340) describes how this balance was achieved. The molecule carries a C-20 fatty diacid conjugation at the lysine at position 20, analogous to the strategy used in semaglutide and tirzepatide, which drives reversible albumin binding and produces an effective half-life of approximately six days in humans. Receptor selectivity was tuned through substitutions informed by the glucagon/GLP-1 alignment, which is why retatrutide retains meaningful glucagon receptor activity without losing incretin coverage.
Three engineering decisions define the compound:
- Triple-receptor balance. Each of the three receptor interactions is tuned to produce functional agonism at physiologically relevant concentrations in the preclinical assays reported by Coskun et al. Retatrutide is not a GLP-1 agonist with added off-target activity.
- Half-life extension. The C-20 fatty diacid at Lys20 enables albumin binding, giving an exposure window long enough for once-weekly dosing in research protocols that mirror the clinical trial schedule.
- Enzymatic stability. The sequence is engineered to resist dipeptidyl peptidase-4 (DPP-4) cleavage at the N-terminus, which would otherwise rapidly inactivate the peptide as happens with native GLP-1.
The practical consequence is a compound that behaves as a single pharmacological unit rather than a cocktail. Triple receptor co-activation occurs simultaneously from a single molecular species, which is what makes retatrutide scientifically distinct from combination dosing of separate GLP-1 and glucagon agonists.
Triple receptor pharmacology: GIP, GLP-1, and glucagon
Understanding why retatrutide data diverges from tirzepatide and semaglutide studies requires a working model of what each receptor pathway contributes, and how simultaneous activation may differ from the sum of individual effects. The pillar guide covers class comparison; this section focuses on each arm’s contribution to retatrutide specifically.
GIP receptor arm
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone released from intestinal K cells after nutrient ingestion. Its receptor (GIPR) is expressed across pancreatic beta cells, adipose tissue, bone, and central nervous system regions involved in appetite regulation.
In retatrutide, GIPR agonism contributes the same glucose-dependent insulinotropic effect and adipose modulation attributed to tirzepatide’s GIP arm. The GIP component potentiates GLP-1 receptor engagement and is believed to contribute to central appetite-regulation effects. Retatrutide inherits this dual-incretin foundation before layering the glucagon arm on top.
GLP-1 receptor arm
GLP-1 receptor activation reduces appetite through hypothalamic and brainstem circuits, slows gastric emptying, and drives glucose-dependent insulin secretion from pancreatic beta cells. It is the primary mechanism of action for semaglutide and the best-characterised receptor in the incretin class.
Retatrutide’s GLP-1R arm supplies the appetite and insulinotropic foundation shared with the rest of the GLP-1 class. The preclinical literature suggests that co-activation of GIP and glucagon receptors alongside GLP-1R modulates downstream signalling in ways that amplify certain metabolic outcomes beyond GLP-1R agonism alone.
Glucagon receptor arm
The glucagon receptor (GCGR) arm is what makes retatrutide mechanistically distinct from every approved and late-stage compound in the incretin class. Glucagon has historically been framed as a counter-regulatory hormone that raises blood glucose, an effect that would appear counterproductive in a metabolic research context.
Research over the past decade has clarified that glucagon’s metabolic role is substantially broader when GCGR activation occurs alongside simultaneous GLP-1R engagement. Habegger et al. 2010 (PMID: 20957001) provides the foundational review underpinning the triple-agonist design rationale.
When GCGR activation is paired with GLP-1R engagement, three effects persist that dual-agonist compounds cannot fully replicate:
- Hepatic fat oxidation. GCGR activation drives preferential lipid oxidation in the liver, which is the mechanistic basis for the hepatic steatosis results seen in retatrutide preclinical and clinical trial cohorts.
- Resting energy expenditure. The glucagon arm elevates basal metabolic rate via brown adipose tissue and hepatic pathways that are not downstream of GLP-1R or GIPR.
- Glucose neutrality via incretin counterbalance. The glucose-raising effect of GCGR agonism is attenuated when GLP-1R is simultaneously activated, allowing the energy expenditure and lipolytic arms to persist without compromising glycaemic control in preclinical models.
This synergy is why retatrutide data diverges most sharply from dual-agonist results in liver fat and energy-expenditure endpoints. In the Phase 2 MASLD sub-study, Sanyal et al. 2024 (Nature Medicine; PMID: 38388735) reported mean liver fat reductions exceeding 80 percent at 48 weeks, with the majority of subjects achieving complete resolution of hepatic steatosis on imaging. That outcome is attributed specifically to the glucagon arm and is one of the clearest examples of triple agonism producing results dual agonists have not replicated.
Clinical trial program: discovery to TRIUMPH
Retatrutide has progressed through a structured clinical program anchored by the Coskun 2022 discovery paper and the Jastreboff 2023 Phase 2 NEJM publication. Phase 2 results exceeded class expectations and triggered rapid advancement into the multi-arm Phase 3 TRIUMPH program. Cross-class comparisons sit in the dedicated comparison article; this section covers the retatrutide-only trial record.
| Trial | n | Dose range | Duration | Primary endpoint | Key result |
|---|---|---|---|---|---|
| Discovery / Phase 1 Coskun et al. 2022, Cell Metabolism PMID: 35985340 |
~60 | 0.1-6 mg | 12 weeks | Safety, PK, PD | Dose-dependent weight change, ~6 day effective half-life confirmed, tolerability profile consistent with incretin class |
| Phase 2 Jastreboff et al. 2023, NEJM PMID: 37366315 |
338 | 1-12 mg | 48 weeks | Percent body weight change vs placebo | Mean -24.2 percent body weight at 12 mg arm; MASLD sub-cohort showed marked hepatic fat reduction |
| MASLD Phase 2 sub-study Sanyal et al. 2024, Nature Medicine PMID: 38388735 |
~100 | 1-12 mg | 48 weeks | Liver fat content (MRI-PDFF) | >80 percent mean liver fat reduction at highest dose; majority achieved hepatic steatosis resolution on imaging |
| TRIUMPH-1 (Phase 3) | ~2,500 | 4-12 mg | 72 weeks | Weight change in obesity | Active – primary obesity trial arm |
| TRIUMPH-2 (Phase 3) | ~400 | 4-12 mg | 72 weeks | Weight change, T2D population | Active – obesity with type 2 diabetes |
| TRIUMPH-3 (Phase 3) | ~1,700 | 4-12 mg | 72 weeks | MACE risk reduction | Active – cardiovascular outcome population |
| TRIUMPH-4 (Phase 3) | ~800 | 4-12 mg | 52 weeks | Weight change and knee pain (KOOS) in obesity plus osteoarthritis | Reported ~23.7 percent mean weight reduction at 12 mg with significant KOOS pain improvement vs placebo (see TRIUMPH-4 result coverage) |
The Jastreboff Phase 2 paper remains the primary pharmacology reference because it established the full dose-response relationship across 1 to 12 mg and supplied the benchmark -24.2 percent weight-change figure later Phase 3 readouts are measured against. TRIUMPH-4 supplied the first Phase 3 confirmation of that magnitude and is covered in detail in the dedicated TRIUMPH-4 article.
Retatrutide vs tirzepatide vs semaglutide: key points
The full head-to-head sits in the comparison article, and class-level pharmacology belongs in the pillar guide. This section captures the retatrutide-specific differentiators that matter for research design choices:
| Feature | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptor targets | GLP-1R + GIPR + GCGR | GLP-1R + GIPR | GLP-1R only |
| Phase 2 headline weight change | -24.2% (Jastreboff 2023, 48 wk) | Not applicable (approved via Phase 3) | Not applicable (approved via Phase 3) |
| Phase 3 headline weight change | ~-23.7% (TRIUMPH-4, 52 wk) | ~-22.5% (SURMOUNT-1, 72 wk) | ~-14.9% (STEP-1, 68 wk) |
| Approximate effective half-life | ~6 days | ~5 days | ~7 days |
| Liver fat reduction in published trials | Very high (>80% in MASLD Phase 2 sub-study) | High | Moderate |
| Regulatory status | Investigational, Phase 3 | Approved (branded clinical forms) | Approved (branded clinical forms) |
For research design, the glucagon receptor arm is the decisive differentiating variable. If the research question involves hepatic lipid metabolism, resting energy expenditure, thermogenesis, or mechanistic isolation of the glucagon contribution in combined incretin-glucagon signalling, retatrutide provides a pharmacological tool that tirzepatide and semaglutide cannot replicate by design. For receptor-level and pharmacokinetic comparisons beyond this, the head-to-head comparison is the right reference.
Research applications
Retatrutide’s triple-agonist profile has opened research applications that mono- and dual-agonist incretin compounds cannot fully address. The active areas reflect the specific mechanistic contribution of glucagon receptor co-activation:
- Dual vs triple mechanism isolation. Comparative experiments contrasting dual (GLP-1R + GIPR) against triple (GLP-1R + GIPR + GCGR) activation allow direct isolation of the glucagon arm, which is difficult with any other combination of compounds.
- MASLD and hepatic lipid biology. The Phase 2 MASLD sub-study hepatic fat data has made retatrutide a priority compound in liver disease research models. The glucagon arm supplies a mechanistic rationale not available from any GLP-1-only or dual incretin compound.
- Energy expenditure and thermogenesis. GCGR activation elevates resting metabolic rate via hepatic and brown adipose tissue pathways. Research using total energy expenditure as an outcome benefits from retatrutide’s ability to engage this arm alongside incretin signalling.
- Obesity comorbidity models. The TRIUMPH-4 design, testing weight change in subjects with knee osteoarthritis, reflects research interest in how pharmacologically induced weight change affects musculoskeletal and cardiovascular endpoints.
- Pharmacokinetic characterisation. The ~6 day effective half-life, C-20 fatty diacid albumin binding, and DPP-4-resistant sequence make retatrutide a useful reference molecule for SAR and long-acting peptide engineering work.
Reconstitution and laboratory handling
Retatrutide is supplied as a lyophilized (freeze-dried) powder in sealed vials and requires reconstitution before use in research protocols. The general procedure for lyophilized peptides applies; full details live in the reconstitution guide, and concentration calculations can be run in the peptide reconstitution calculator.
- Diluent. Bacteriostatic water (0.9 percent benzyl alcohol) is standard for multi-use research-grade reconstitution. Sterile water for injection is an alternative but reduces the usable window once reconstituted.
- Reconstitution technique. Add diluent slowly along the vial wall rather than directly onto the lyophilized cake. Swirl gently rather than vortexing or shaking, which can cause aggregation and degrade peptide integrity.
- Storage (lyophilized). -20 C, protected from light and moisture. Vials stored under these conditions are typically stable for 24+ months from manufacture date.
- Storage (reconstituted). 2-8 C refrigerated, use within approximately 21 days. Avoid repeated freeze-thaw cycles of reconstituted solution.
- Purity specification. Research-grade retatrutide should be greater than or equal to 98 percent by HPLC, with a batch-specific Certificate of Analysis. Identity confirmation via mass spectrometry against the expected ~4,748 Da molecular weight is standard for high-integrity research protocols.
- Working concentrations. Calculate against the peptide content stated on the COA rather than the gross vial mass, because the C-20 fatty diacid conjugate contributes to total molecular weight without adding receptor activity.
These are laboratory handling procedures for research-use material only. They are not a human dosing protocol.
Frequently asked questions
What receptors does retatrutide target?
Retatrutide simultaneously activates three receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. This triple agonism from a single molecular species is the defining characteristic of the compound and distinguishes it from tirzepatide (GLP-1R and GIPR dual agonist) and semaglutide (GLP-1R only).
What makes retatrutide different from semaglutide?
Semaglutide engages only the GLP-1 receptor. Retatrutide adds GIP receptor and glucagon receptor agonism on top of GLP-1R activity in the same molecule. The glucagon arm is the main mechanistic difference, because it contributes hepatic fat oxidation and resting energy expenditure effects that GLP-1R-only compounds do not produce in preclinical or clinical trial models.
How does retatrutide compare to tirzepatide?
Both compounds share GLP-1R and GIPR agonism, but retatrutide adds glucagon receptor activation as a third arm. In published research data, retatrutide’s Phase 2 weight-change benchmark and MASLD liver fat reductions exceed the comparable figures published for tirzepatide. Tirzepatide is approved for clinical use, while retatrutide remains investigational in the Phase 3 TRIUMPH program. For research contexts focused on hepatic lipid biology or energy expenditure, the glucagon arm is the decisive differentiator.
What is the TRIUMPH program?
TRIUMPH is the Phase 3 clinical trial program for retatrutide conducted by the drug sponsor. It includes TRIUMPH-1 (obesity), TRIUMPH-2 (obesity with type 2 diabetes), TRIUMPH-3 (cardiovascular outcome population), and TRIUMPH-4 (obesity with knee osteoarthritis). TRIUMPH-4 was the first to report a topline result, showing approximately 23.7 percent mean weight change at the 12 mg dose over 52 weeks. Full coverage of the TRIUMPH-4 result lives in the dedicated TRIUMPH-4 article.
Is retatrutide approved?
No. Retatrutide (LY3437943) is not approved by the FDA or any equivalent regulator. It is investigational and is being studied in the Phase 3 TRIUMPH program. Retatrutide is available only for laboratory and research use under a research-chemical classification and is not licensed for clinical or therapeutic use in any jurisdiction. Researchers should confirm current regulatory status in their jurisdiction before initiating protocols.
References
- Coskun T, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycaemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234-1247. PMID: 35985340.
- Jastreboff AM, et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity: a Phase 2 trial. New England Journal of Medicine, 389(6), 514-526. PMID: 37366315.
- Sanyal AJ, et al. (2024). Retatrutide for metabolic dysfunction-associated steatotic liver disease: a Phase 2 sub-study. Nature Medicine, 30. PMID: 38388735.
- Habegger KM, et al. (2010). The metabolic actions of glucagon revisited. Nature Reviews Endocrinology, 6(12), 689-697. PMID: 20957001.
Disclaimer: this article is provided for educational and research reference purposes only. CertaPeptides products are sold exclusively for laboratory and research use. Not for human consumption. Nothing in this article constitutes medical advice, therapeutic recommendation, or dosing guidance for human use. All clinical trial data is reproduced strictly as research context and attributed to the published source. Always consult peer-reviewed literature for experimental protocol design.